Committee Rejects FDA Proposal To Narrow Bioequivalence Margins
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pharmaceutical Science and Clinical Pharmacology Advisory Committee doesn't see the additional criteria as necessary, but FDA could still impose narrower bioequivalence margins over its objections.
You may also be interested in...
Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee agrees with the Office of Generic Drugs that bioequivalence standards should be tighter for generic versions of "critical dose" or "narrow therapeutic index" drugs.
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes
FDA's Office of Generic Drugs is planning a multi-prong approach to boost public confidence in generic drugs, including scientific publications and possible changes in approval guidance, following a series of high-profile concerns raised about the quality of the products
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.